For decades, treating acne has focused on reducing oil production, unclogging pores, and fighting bacteria with antibiotics. But a deeper understanding of the bacteria responsible, Cutibacterium acnes, is opening entirely new treatment possibilities.
What Is Cutibacterium Acnes?
Cutibacterium acnes (formerly called Propionibacterium acnes, or P. acnes) is a gram-positive bacterium that lives naturally within human hair follicles and sebaceous (oil) glands. It is part of the normal skin microbiome and, in small amounts, causes no problems.
How Does C. Acnes Cause Breakouts?
Problems arise when sebum production increases and follicles become blocked. This creates an anaerobic (low-oxygen) environment where C. acnes multiplies rapidly. As the bacteria proliferate, they trigger an immune response, resulting in the redness, swelling, and pus that characterize inflammatory acne.
Why Antibiotic Resistance Is a Growing Problem
Oral and topical antibiotics have long been used to reduce C. acnes populations on the skin. However, antibiotic-resistant strains of C. acnes are now increasingly common, reducing the effectiveness of these treatments over time.
The Future: mRNA Vaccine Technology
One of the most exciting developments in acne research is the application of mRNA technology, the same platform used in COVID-19 vaccines, to specifically target C. acnes. An experimental mRNA vaccine is currently in clinical trials, aiming to train the immune system to neutralize C. acnes without the side effects of systemic antibiotics.
Participate in the Acne Trial at NuLine
NuLine is currently enrolling participants ages 18 to 44 for an acne mRNA vaccine study. Learn more and apply, earn $120 per visit.